drugset
drugset / Trial / NCT00780052

Infusional C-myb ASODN in Advanced Hematologic Malignancies

NCT00780052 ↗

Phase 1 Completed 13 enrolled Abramson Cancer Center at Penn Medicine
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether C-myb Antisense (AS) Oligonucleotides (ODNs)is a possible treatment modality for advanced hematologic malignancies.

Timeline

Start
2002-09
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject c-myb AS ODN Antisense oligonucleotide — Intravenous

Indications

hematopoietic and lymphoid cell neoplasm